News

As the first company to file an abbreviated new drug application (ANDA) containing a Paragraph IV certification for this product, Teva said that it has been awarded a

According to the company, two 600-subject trials will be conducted simultaneously in approximately 180 study centers throughout the US and Canada. Subjects will receive rifaximin or placebo (1:1

Under the terms of the agreement, China Yongxin will have exclusive rights to this brand in Jilin Province, which includes the City of Changchun and has a total

ATL/TV1102 Phase IIa trial was a randomized, double-blind, placebo-controlled clinical trial of ATL/TV1102. The goal of the trial was to obtain preliminary evidence of ATL/TV1102’s effectiveness in reducing

In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV dihydroergotamine (DHE), but did not activate receptors associated with side effects frequently

The first clinical study evaluated the pharmacokinetics, bioequivalence and safety of needle-free sumatriptan DosePro, compared to a needle-based autoinjector, Imitrex STATdose used in the treatment of migraine. DosePro

The two-year investigation uncovered evidence that money changed hands in return for the falsification of clinical data required for drug licences. The discovery led to the suspension of

Each unit was priced at $0.50 and consisted of one share of the company’s common stock and one warrant to purchase one-half share of common stock. Warrants are

This compound is an internally developed, selective, orally-bioavailable small molecule for the treatment of relapsed and refractory chronic myelogenous leukemia. Mike Grey, CEO of SGX Pharmaceuticals, said: “Filing